Tesamorelin is a stabilized synthetic peptide analog of growth-hormone-releasing hormone (GHRH). It is a 44-residue GHRH(1-44) sequence carrying an N-terminal modification that increases its stability relative to native GHRH, and it is studied in preclinical research as a tool compound for investigating GHRH-receptor signaling and the growth-hormone axis in research models.
Tesamorelin does not occur as a discrete native peptide in this modified form, which makes it a fully synthetic research compound. As supplied for research, it is a lyophilized powder that is water-soluble on reconstitution.
Verified dataVerified compound data
| Property | Value |
|---|---|
| Compound name | Tesamorelin (stabilized GHRH(1-44) analog) |
| CAS number | 218949-48-5 (free peptide); 901758-09-6 (acetate salt) |
| PubChem CID | 16137828 |
| Molecular formula | C221H366N72O67S |
| Molecular weight | ~5135.86 g/mol |
| Length | 44 residues (modified GHRH(1-44) analog) |
| Physical form | Lyophilized powder |
Data verified against PubChem (CID 16137828), ChemicalBook (CAS 218949-48-5, MW 5135.86), and Wikipedia. The acetate-salt form carries a separate CAS (901758-09-6); values above reflect the free peptide.
MechanismResearch-context mechanism
In preclinical literature, Tesamorelin is studied as an agonist at the GHRH receptor. In animal and in vitro research models, GHRH-receptor agonism is associated with stimulation of growth-hormone release from the pituitary in a research-model context. The N-terminal modification is studied for its effect on peptide stability against enzymatic degradation. These mechanisms are described strictly in the context of in vitro and animal research models; they are not established human-use mechanisms, and no therapeutic application is described or implied.
Research summaryCurrent research summary
Tesamorelin appears in preclinical literature as a stabilized GHRH-analog research tool. Reported research areas include:
- GHRH-receptor agonism and binding studies
- Growth-hormone-axis signaling research models (animal level)
- Peptide-stability and enzymatic-degradation studies
- Pharmacokinetic profiling of the modified analog vs native GHRH (preclinical)
The existing body of work referenced here is framed at the in vitro and animal-research level. Vantage supplies Tesamorelin strictly as a research compound; no human therapeutic use is described, claimed, or implied. All framing is laboratory research only.
QuestionsFrequently Asked Questions
What is Tesamorelin?
Tesamorelin is a stabilized synthetic GHRH-analog peptide (a modified 44-residue GHRH(1-44) sequence) studied in preclinical GHRH-receptor and growth-hormone-axis research models. It is a research compound supplied as a lyophilized powder and is not approved for human use in this research context.
What is the molecular formula of Tesamorelin?
The molecular formula of Tesamorelin is C221H366N72O67S, with a molecular weight of approximately 5135.86 g/mol (PubChem CID 16137828).
What is the CAS number for Tesamorelin?
The CAS registry number for the free Tesamorelin peptide is 218949-48-5; the acetate salt carries CAS 901758-09-6.
What class of peptide is Tesamorelin?
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH), studied as a GHRH-receptor research tool. It is a 44-residue peptide with an N-terminal modification that increases stability relative to native GHRH.
How is Tesamorelin stored and reconstituted in a research setting?
Lyophilized Tesamorelin is stored at 2 to 8°C, protected from light and humidity. It is reconstituted with a suitable sterile solvent, is water-soluble, and reconstituted material is held at 4°C and used within about 30 days, avoiding repeated freeze-thaw cycles.
Is Tesamorelin sold here for human use?
No. Tesamorelin is supplied strictly as a research compound for laboratory use and is not intended for human consumption.
For research use only. Not for human or veterinary use. Not approved by the FDA. 21+
- HPLC + MS tested, every batch
- U.S. synthesized
- Batch COA on the product page
$63View compound